Diabetes Therapeutics Market Size Projected To Increase From $188.18 Billion To $278.96 Billion During The Forecast Period
Delivering more actionable and strategically valuable research, The Business Research Company’s 2026 market reports feature market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights.
Diabetes Therapeutics Market Expected To Reach $278.96 Billion By 2030 At 10.3% CAGR
The diabetes therapeutics market has experienced significant expansion in recent times, with projections indicating an increase from $170.06 billion in 2025 to $188.19 billion in 2026, reflecting a compound annual growth rate (CAGR) of 10.7%. This historical growth has been driven by several factors, including the restricted accessibility of advanced therapeutic options, a heavy dependence on conventional oral anti-diabetic medications, insufficient awareness regarding preventive healthcare measures, limited distribution networks, and the escalating prevalence of type 2 diabetes.
The diabetes therapeutics market is anticipated to experience swift expansion over the coming years, reaching an estimated value of $278.96 billion by 2030, with a compound annual growth rate (CAGR) of 10.3%. This projected growth during the forecast period is driven by factors such as the creation of novel insulin analogs, the broadening of combination therapies, the uptake of digital tools for diabetes management, improvements in healthcare infrastructure dedicated to diabetes care, and the incorporation of telemedicine alongside remote monitoring capabilities. Key trends shaping this period include the global surge in diabetes prevalence, the growing utilization of GLP-1 receptor agonists and SGLT-2 inhibitors, the expansion of online and retail pharmacy channels, an intensified emphasis on customized diabetes management, and heightened awareness surrounding preventive care and early detection.
Download A Free Sample Report For Comprehensive Market Insights:
Diabetes Therapeutics Market Opportunity Drivers: What Is Creating New Revenue Potential?
The ongoing rise in obesity rates is anticipated to fuel expansion in the diabetes therapeutics market in the coming years. Obesity, characterized by an abnormal accumulation of body fat that poses health risks, serves as a significant contributor to type 2 diabetes. This trend is largely driven by a heightened intake of calorie-dense diets, as more individuals consume processed and fast foods rich in sugar and fat, combined with reduced physical activity, which results in excessive weight gain. Diabetes therapeutics address obesity by enhancing blood sugar regulation and facilitating weight loss through agents like GLP-1 receptor agonists, which curb appetite and slow digestive processes, thereby improving overall metabolic function in those who are obese. For example, a May 2024 report from the Office for Health Improvement and Disparities, a UK governmental body, indicated that between 2022 and 2023, roughly 64% of adults aged 18 and older were categorized as overweight or obese, marking an increase from 63.8% in the prior year. Consequently, the growing prevalence of obesity is propelling the diabetes therapeutics market forward.
Diabetes Therapeutics Market Segments: Where Are The Largest Growth Opportunities?
The diabetes therapeutics market covered in this report is segmented –
1) By Drug: Oral Anti-Diabetic Drugs, Insulin, Non-Insulin Injectable Drug, Combination Drug
2) By Type: Diabetes 1, Diabetes 2
3) By Route Of Administration: Oral, Subcutaneous, Intravenous
4) By Distribution Channel: Online Pharmacies, Hospital Pharmacies, Retail Pharmacies
5) By Application: Preventive, Treatment Or Care
Subsegments:
1) By Oral Anti-Diabetic Drugs: Biguanides, Sulfonylureas, DPP-4 Inhibitors, SGLT-2 Inhibitors, Thiazolidinediones, Meglitinides, Alpha-Glucosidase Inhibitors
2) By Insulin: Rapid-Acting Insulin, Short-Acting Insulin, Intermediate-Acting Insulin, Long-Acting Insulin, Premixed Insulin
3) By Non-Insulin Injectable Drug: GLP-1 Receptor Agonists, Amylin Analogs
4) By Combination Drug: Oral Combination Therapies, Oral and Injectable Combination Therapies
Diabetes Therapeutics Market Innovation Trends Driving Future Development
Major players within the diabetes therapeutics sector are concentrating on the development of advanced approaches like cognitive behavioral therapy (CBT) to improve customized diabetes care and achieve better blood sugar control in individuals with type 2 diabetes. This evidence-based psychological treatment, known as cognitive behavioral therapy, is organized to assist patients in recognizing and adjusting detrimental thinking patterns and behaviors. An example of this progress is seen in October 2023, when Better Therapeutics Inc., a digital therapeutic company based in the United States, introduced AspyreRx, a specialized digital tool for diabetes management. This app, which gained FDA clearance for treating type 2 diabetes, delivers tailored cognitive behavioral therapy to individuals 18 years and older, promoting lifestyle changes that enhance the control of their condition. Previously designated as BT-001, AspyreRx achieved meaningful and clinically confirmed reductions in A1c levels relative to usual care, along with enhancements in blood pressure, weight, emotional state, and overall quality of life, as demonstrated through a randomized controlled trial.
Diabetes Therapeutics Market Major Participants And Competitive Dynamics
Major companies operating in the diabetes therapeutics market are Pfizer Inc., Merck & Co Inc., Novartis AG, Sanofi S.A., AstraZeneca PLC, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Novo Nordisk A/S, Boehringer Ingelheim International GmbH, Biocon Biologics Limited, MannKind Corporation, Lexicon Pharmaceuticals Inc., Adocia S.A., Oramed Pharmaceuticals Inc.
Access The Complete Diabetes Therapeutics Market Report:
Diabetes Therapeutics Market Leading Geography: Which Region Generates The Most Revenue?
North America was the largest region in the diabetes therapeutics market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the diabetes therapeutics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=home_page_test
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
